Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock
BOULDER, Colo., Oct. 27, 2023 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases,…